Abstract OT2-02-08: A phase 2 randomized, double-blind, placebo-controlled study of ribociclib or placebo in combination with endocrine therapy for the treatment of premenopausal and postmenopausal Chinese women with HR+, HER2−, advanced breast cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs19-ot2-02-08
Abstract: Background: Ribociclib (RIB) is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that has demonstrated efficacy and safety in combination with endocrine therapy (ET) for the treatment of advanced breast cancer (ABC), but to date no studies… read more here.
Keywords: combination; placebo combination; therapy; premenopausal postmenopausal ... See more keywords